Pfizer and BioNTech SE have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against COVID-19 to EU Member States, with an option to request an additional 100 million doses. Deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization. The vaccine doses will be produced at BioNTech’s German manufacturing sites, as well as Pfizer’s manufacturing site i...